Back to top
more

Hims & Hers Health (HIMS)

(Delayed Data from NYSE)

$15.85 USD

15.85
18,131,491

-0.19 (-1.18%)

Updated Aug 8, 2024 04:00 PM ET

After-Market: $15.85 0.00 (0.00%) 5:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 43% (107 out of 250)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Is it Wise to Hold Teleflex (TFX) Stock in Your Portfolio Now?

Teleflex (TFX) holds strong momentum in the Interventional arm and a favorable solvency. Yet, macroeconomic impacts and competitive environment trigger concerns.

QIAGEN (QGEN) Backs New AAP Guidelines Supporting QFT-Plus Test

QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.

Neogen (NEOG) Expands in Food Safety With Petrifilm Feeder Launch

Neogen (NEOG) launches Petrifilm Automated Feeder, which allows automatic feeding and enumeration of up to 300 petrifilm plates in 33 minutes. The system improves the efficiency of food safety testing labs.

Thermo Fisher's (TMO) New Launch Speeds Up pDNA Purification

Thermo Fisher (TMO) introduces the Thermo Scientific KingFisher PlasmidPro, the fully automated maxi-scale pDNA purification system.

Charles River's (CRL) RMS Growth Aids Amid FX Headwind

Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.

Quest Diagnostics (DGX) Inks Deal to Acquire Allina Health

Quest Diagnostics (DGX) signs an agreement to acquire Allina Health's select laboratory assets. The deal is aimed at expanding Quest Diagnostics' laboratory services across Minnesota and western Wisconsin.

Bruker's (BRKR) Strategic Buyouts Aid Amid Macroeconomic Woes

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand, further bolstered by the addition of Inscopix's neuroscience research tools.

Boston Scientific (BSX) DBS Programming Software Gets CE Mark

Boston Scientific (BSX) secures CE Mark for the DBS image-guided programming software, Vercise Neural Navigator 5.

Is It Apt to Hold Quest Diagnostics (DGX) Stock for Now?

Strength in the core business bodes well for Quest Diagnostics (DGX). However, mounting debt levels and reduced COVID-19 testing revenues pose concerns.

Charles River (CRL) Inks CDMO Deal With Gates Institutes

Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.

Asensus Surgical (ASXC) Announces New Hospital Tie-Up on Senhance

Asensus Surgical (ASXC) announces an agreement with St. Marianna University School of Medicine Yokohama City Seibu Hospital to lease its Senhance Surgical System.

Illumina (ILMN) Rises on Conclusion of GRAIL Divestment

With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.

Medtronic (MDT) Shares Positive Data for MiniMed 780G System

Medtronic (MDT) presents more compelling data showcasing the benefits of the MiniMed 780G system.

Hims & Hers Health, Inc. (HIMS) Flat As Market Sinks: What You Should Know

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $22.15, marking no change from the previous day.

Abbott's (ABT) EPD Expansion Continues Despite FX Headwind

Banking on the successful execution of its Branded Generic operating model, Abbott's (ABT) EPD is well-positioned for sustained growth in many of the growing pharmaceutical markets.

Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval

Valneva's (VALN) IXCHIQ, the world's only licensed chikungunya vaccine, is a critical tool in combating this public health threat.

Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS

Alcon (ALC) gets FDA 510(k) clearance for its Unity VCS and Unity CS. The company will start a thorough program to get real-world feedback before the systems' commercial launch in 2025.

Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes

Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.

Nalak Das headshot

5 Medical Info Systems Stock to Buy for a Stable Portfolio

We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.

IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds

IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.

Inspira (IINN) Unveils Business Targets for 2024-25

Inspira (IINN) discloses business goals for 2024-25 with the rapid promotion of INSPIRA ART100 and the development of INSPIRA ART (Gen 2).

Quest Diagnostics (DGX) Gains From New M&As Amid Competition

In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share gains driven by the competitive strength of its scale and innovative offerings.

Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year?

Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.

Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System

Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.

Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?

Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.